Device
PuraPly™ Antimicrobial Wound Matrix
PuraPly™ Antimicrobial Wound Matrix is a medical device with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph not_applicable
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
N/A
Trials by Phase
N/A1 (100.0%)
Trials by Status
completed375%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
terminatednot_applicable
PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.
NCT03502824
completed
The RESPOND Registry
NCT03286452
completed
PuraPly™ Antimicrobial Wound Matrix and Wound Management
NCT03070938
completed
Prospective PuraPly™ AM Case Series Study
NCT03070925
Clinical Trials (4)
Showing 4 of 4 trials
NCT03502824Not Applicable
PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.
NCT03286452
The RESPOND Registry
NCT03070938
PuraPly™ Antimicrobial Wound Matrix and Wound Management
NCT03070925
Prospective PuraPly™ AM Case Series Study
All 4 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 4